Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2013

View Archived Issues

Researchers at AbbVie synthesize new compounds for RSV infection

Tris Pharma and FSC Laboratories sign commercialization agreement for Karbinal ER

Comfrey root extract with methyl nicotinate effective for low back pain

Crinetics Pharmaceuticals receives grant to develop drugs for pituitary tumors

ThromboGenics and Bicycle Therapeutics to collaborate on bicyclic peptide inhibitors

Novel genetic locus associated with a childhood gastrointestinal disease identified

Proof-of-concept for gene therapy-mediated retinal rescue using a novel transgenic mouse model

Gene-centric association study of complications associated with sickle cell disease

XBiotech begins preclinical study of antibody therapy for MRSA

First milestone reached within Karo Bio and Pfizer's RORgamma collaboration

KemPharm expands pain therapy pipeline with KP-606

FDA accepts complete response submission to Aveed NDA

Bayer HealthCare applies for approval of regorafenib for GIST in Europe

Tablet formulation of Boldocynara shows efficacy in patients with functional digestive disorders

RQx Pharmaceuticals patents new signal peptidase inhibitors

New York University and USC patent novel agents for cancer and other disorders

New kinase inhibitors synthesized at Merck KGaA

Extract from S. scardica shows promise for Alzheimer's disease treatment

Otsuka Pharmaceutical to acquire Astex Pharmaceuticals

Viamet begins phase II studies of antifungal VT-1161

Medivir and Daewoong discontinue development of hepatitis B compound

Novel vaccines for tuberculosis disclosed

Almac Discovery and Queen's University Belfast form new partnership

Plasma uridine as a biomarker of ornithine transcarbamylase deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...